Logo

Endovascular Engineering Obtains IDE Approval from the US FDA for its Hēlo Thrombectomy System to Treat Pulmonary Embolism

Share this
Endovascular Engineering

Endovascular Engineering Obtains IDE Approval from the US FDA for its Hēlo Thrombectomy System to Treat Pulmonary Embolism

Shots:

  • Following the conclusion of the 25-patient feasibility study, the US FDA has granted Investigational Device Exemption (IDE) approval to Endovascular Engineering’s Hēlo Thrombectomy System for conducting (ENGULF) study in the US
  • The (ENGULF) trial aims to investigate the safety and efficacy of the Hēlo Thrombectomy System for the treatment of pulmonary embolism (PE)
  • The Hēlo Thrombectomy System employs a dual-action methodology taking place within a self-expanding funnel, as the high-speed agitator actively engages and removes clots under physician-controlled suction

Ref: PR Newswire | Image: Endovascular Engineering

Related News:- Venus Remedies Reports P-I Study Results of Enoxaparin Biosimilar to Prevent Arterial and Venous Thromboembolism

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

 

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions